Authors, Editors, Reviewers

Manuscript Submission, Check or Review Login can be found directly on our journal pages.


Journal Overview

Institutional Login

Karger supports the identity and access management tools Shibboleth and OpenAthens for subscribing institutions.


Institutional Login

Review

The Nightmare of Indeterminate Follicular Proliferations: When Liquid-Based Cytology and Ancillary Techniques are not a Moon Landing but a Realistic Plan

Rossi E.D.a · Fadda G.a · Schmitt F.b-d

Author affiliations

aDivision of Anatomic Pathology and Histology, Agostino Gemelli School of Medicine, Catholic University of Sacred Heart, Rome, Italy; bInstituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; cDepartment of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, and dDepartment of Pathology, University Health Network, Toronto, Ont., Canada

Related Articles for ""

Acta Cytologica 2014;58:543-551

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.


Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.


To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Review

Received: April 08, 2014
Accepted: May 06, 2014
Published online: July 16, 2014
Issue release date: November – December

Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 0

ISSN: 0001-5547 (Print)
eISSN: 1938-2650 (Online)

For additional information: https://www.karger.com/ACY

Abstract

Objective: Thyroid nodules are a common finding in the general population, including both nonneoplastic and neoplastic entities. Fine-needle aspiration cytology (FNAC) is the first tool for evaluating thyroid nodules. In spite of its high diagnostic accuracy, 25% of nodules result in the category of follicular neoplasms (FN), with varying risk of malignancy and different management strategies. Study Design: The use of ancillary techniques is reshaping the practice of FNAC. These tools can significantly empower the morphological diagnosis and prognosis of thyroid nodules, allowing a more accurate prediction of the nature of the lesion. Several studies have underlined the role of single or multiple testing for the category of FN as strong indicators of cancer. Every cytological preparation can be used for the application of ancillary techniques but the introduction of liquid-based cytology (LBC) might facilitate the application. Results: Our experience involving an immunocytochemical panel made up of HBME-1 and galectin-3 pointed to an 81% overall diagnostic accuracy in discriminating between low and high risk of malignancy in FN. Conclusions: The application of these techniques on LBC represents an adjunct to the morphological evaluation of FN. They represent a critical and challenging, but also a feasible, tool in the preoperative diagnoses, allowing specific prognostic and predictive details regardless of the cytological preparation.

© 2014 S. Karger AG, Basel




Related Articles:


References

  1. Rossi ED, Morassi F, Santeusanio G, Zannoni GF, Fadda G: Thyroid fine-needle aspiration cytology processed by ThinPrep: an additional slide decreased the number of inadequate results. Cytopathology 2010;21:97-102.
  2. Rossi ED, Raffaelli M, Minimo C, Mule A, Lombardi CP, Vecchio FM, Fadda G: Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies. Cancer 2005;105:87-95.
  3. Cochand-Priollet B, Prat JJ, Polivka M, Thienpont L, Dahan H, Wassef M, Guillausseau PJ: Thyroid fine-needle aspiration: the morphological features on ThinPrep slide preparations. Eighty cases with histological control. Cytopathology 2003;14:343-349.
  4. Ravetto C, Colombo L, Dottorini ME: Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinomas. A retrospective study in 37,895 patients. Cancer Cytopathol 2000;90:357-363.
  5. Poller DN, Ibrahim AK, Cummings MH, Mikel JJ, Boote D, Perry M: Fine-needle aspiration of the thyroid. Importance of an indeterminate diagnostic category. Cancer Cytopathol 2000;90:239-244.
  6. Papanicolaou Society of Cytopathology Task Force on Standards of Practice: Guidelines of the Papanicolaou Society of Cytopathology for the examination of fine needle aspiration specimens from thyroid nodules. Mod Pathol 1996;9:710-715.
    External Resources
  7. American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer; Cooper DS, Doherty GM, Haugen BR, et al: Revised management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.
  8. Gharib H, Papini E, Valcavi R, Baskin HJ, Crescenzi A, Dottorini ME, Duick DS, Guglielmi R, Hamilton CR, Zeiger MA, Zini M; AACE/AME/ETA Task Force on Thyroid Nodules: American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2006;12:63-102.
  9. Lobo C, McQueen A, Beale T, Kocjan G: The UK Royal College of Pathologists' thyroid fine-needle aspiration diagnostic classification is a robust tool for the clinical management of abnormal thyroid nodules. Acta Cytol 2011;55:499-506.
  10. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK, Frable WJ: Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Fine-Needle Aspiration State-of-Science Conference. Diagn Cytopathol 2008;36:425-437.
  11. Cibas ED, Ali SZ: The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol 2001;32:658-665.
  12. Baloch ZW, Mandel SJ, LiVolsi VA: Are we ready to modify the Bethesda thyroid fine-needle aspiration classification scheme? Cancer Cytopathol 2013;121:171-174.
  13. Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW: The Bethesda system for reporting thyroid cytopathology: a meta-analysis. Acta Cytol 2012;56:333-339.
  14. British Thyroid Association, Royal College of Physicians: Guidelines for the Management of Thyroid Cancer, ed 2. Report of the Thyroid Cancer Guidelines Update Group. London, Royal College of Physicians, 2007.
  15. Fadda G, Basolo F, Bondi A, Bussolati G, Crescenzi A, Nappi O, Nardi F, Papotti M, Taddei G, Palombini L; SIAPEC-IAP Italian Consensus Working Group: Cytological classification of thyroid nodules. Proposal of the SIAPEC-IAP Italian Consensus Working Group. Pathologica 2010;102:405-408.
    External Resources
  16. Cochand Priollet B, Schmitt FC, Totsch M, Vielh P: The Bethesda terminology for reporting thyroid cytopathology: from theory to practice in Europe. Acta Cytol 2011;55:507-517.
  17. Fadda G, Rossi ED, Raffaelli M, Pontecorvi A, Sioletic S, Morassi F, Lombardi CP, Zannoni GF, Rindi G: Follicular thyroid neoplasms can be classified as low and high risk according to HBME-1 and galectin-3 expression on liquid-based fine-needle cytology. Eur J Endocrinol 2011;165:447-453.
  18. De Matos LL, Del Giglio AB, Matsubayashi CO, De Lima Farah M, Del Giglio A, Da Silva Pinhal MA: Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol 2012;7:97-101.
  19. Paunovic I, Isic T, Havelka M, Tatic S, Cvejic D, Savin S: Combined immunohistochemistry from thyroid peroxidase, galectin-3 and HBME-1 in different diagnosis of thyroid tumors. APMIS 2012;120:368-379.
  20. Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM: Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010;176:2067-2081.
  21. Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, Palestini N, Ghigo E, Papotti M, Bussolati G, Martegani MP, Pantellini F, Carpi A, Giovagnoli MR, Monti S, Toscano V, Sciacchitano S, Pennelli GM, Mian C, Pelizzo MR, Rugge M, Troncone G, Palombini L, Chiappetta G, Botti G, Vecchione A, Bellocco R; Italian Thyroid Cancer Study Group (ITCSG): Galectin-3 expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol 2008;9:543-549.
  22. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT, et al: Galectin-3, fibronectin-1, CITED-1, HBME-1 and cytocheratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 2005;18:48-57.
  23. Correia-Rodrigues HG, Nogueira De Pontes AA, Adan LF: Use of molecular markers in samples obtained from preoperative aspiration of thyroid. End J 2012;59:417-424.
  24. Saleh HA, Hammoud J, Zakaria R, Khan AZ: Comparison of ThinPrep and cell block preparation for the evaluation of thyroid epithelial lesions on fine-needle aspiration biopsy. Cytojournal 2008;5:3.
  25. Cochand-Priollet B, Dahan H, Laloi-Michelin M, Polivka M, Saada M, Herman P, Guillausseau PJ, Hamzi L, Poté N, Sarfati E, Wassef M, Combe H, Raulic-Raimond D, Chedin P, Medeau V, Casanova D, Kania R: Immunocytochemistry with cytokeratin-19 and HBME-1 increases the diagnostic accuracy of thyroid fine-needle aspirations. Preliminary report of 150 liquid-based fine-needle aspirations with histological control. Thyroid 2011;21:1067-1073.
  26. Dabbs D, Abendroth CS, Grenko RT, Wang X, Gail ER: Immunocytochemistry on the ThinPrep processor. Diagn Cytopathol 1997;17:388-392.
  27. Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW: Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 2002;126:710-713.
    External Resources
  28. Fadda G, Rossi ED, Raffaelli M, Mulè A, Pontecorvi A, Miraglia A, Lombardi CP, Vecchio FM: Fine-needle aspiration biopsy of thyroid lesions processed by thin-layer cytology: one-year institutional experience with histologic correlation. Thyroid 2006;16:975-981.
  29. Fadda G, Rossi ED: Liquid-based cytology in fine-needle aspiration biopsies of the thyroid gland. Acta Cytol 2011;55:389-400.
  30. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Push S, Mechtersheimer G, Zentgraf H, Von Deimling A: Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2001;122:11-19.
  31. Rossi ED, Martini M, Capodimonti S, Cenci T, Straccia P, Angrisani B, Ricci C, Lanza P, Lombardi CP, Pontecorvi A, Larocca LM, Fadda G: Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: a cyto-histological institutional experience. Cancer Cytopathol 2014, Epub ahead of print.
  32. Schmitt FC, Barroca H: Role of ancillary studies in fine-needle aspiration from selected tumors. Cancer Cytopathol 2012;120:145-160.
  33. Schmitt FC, Longatto-Filho A, Valent A, Vielh P: Molecular techniques in cytopathology practice. J Clin Pathol 2008;61:258-267.
  34. Longatto-Filho A, Goncalves AE, Martinho O, Schmitt FC, Reis RM: Liquid-based cytology in DNA-based molecular research. Anal Quant Cytol Histol 2009;31:395-400.
    External Resources
  35. Rossi ED, Martini M, Capodimonti S, Lombardi CP, Pontecorvi A, Vellone VG, Zannoni GF, Larocca LM, Fadda G: BRAF (V600E) mutation analysis on LBC-processed aspiration biopsies predicts bilaterality and nodal involvement in papillary thyroid microcarcinoma. Cancer Cytopathol 2013;121:291-297.
  36. Rossi ED, Martini M, Capodimonti S, Straccia P, Cenci T, Lombardi CP, Pontecorvi A, Larocca LM, Fadda G: Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma. Eur J Endocrinol 2013;168:853-859.
  37. Chang H, Lee H, Yoon SO, Kim H, Kim A, Kim BH: BRAF (V600E) mutation analysis of liquid-based preparation-processed fine-needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma. Hum Pathol 2012;43:89-95.
  38. Nikiforova MN, Nikiforov Y: Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009;19:1351-1361.
  39. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN: Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009;94:2092-2098.
  40. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Máximo V, Botelho T, Seruca R, Sobrinho-Simões M: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003;22:4578-4580.
  41. Cheung CC, Carydis B, Ezzat S, Bedard YC, Asa SL: Analysis of ret/PTC gene rearrangements refines the fine-needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab 2001;86:2187-2190.
  42. Ohori NP, Nikiforova MN, Schoedel KE, LeBeau SO, Hodak SP, Seethala RR, Carty SE, Ogilvie JB, Yip L, Nikiforov YE: Contribution of molecular testing to thyroid fine-needle aspiration cytology of ‘follicular lesion of undetermined significance/atypia of undetermined significance'. Cancer Cytopathol 2010;118:17-23.
  43. Moses W, Weng J, Sansano I, Peng M, Khanafshar E, Ljung BM, Duh QY, Clark OH, Kebebew E: Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg 2010;34:2589-2594.
  44. Xing M: BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrinol Rev 2007;28:742-762.
  45. Puxeddu E, Durante C, Avenia N, Filetti S, Russo D: Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab 2008;19:138-145.
  46. Musholt TJ, Fottner C, Weber M, Eichhorn W, Pohlenz J, Musholt PB, Springer E, Schad A: Detection of papillary carcinoma by analysis of BRAF and RET/PTC1 mutations in fine needle aspiration biopsies of thyroid nodules. World J Surg 2010;34:2595-2603.
  47. Colanta A, Lin O, Tafe L, Ghossein R, Nafa K, Mitchell T, Ladanyi M, Arcila M: BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis. Acta Cytol 2011;55:563-569.
  48. Mathur A, Weng J, Moses W: A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine-needle aspiration biopsies. Surgery 2010;148:1176-1177.
  49. Niemeier LA, Kuffner Akatsu H, Song C, Carty SE, Hodak SP, Yip L, Ferris RL, Tseng GC, Seethala RR, Lebeau SO, Stang MT, Coyne C, Johnson JT, Stewart AF, Nikiforov YE: A combined molecular-pathologic score improves risk stratification of papillary microcarcinoma. Cancer 2011;118:2069-2077.
  50. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR: Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012;367:705-715.
  51. Faquin W: Can a gene expression classifier with high negative predictive value solve the indeterminate thyroid fine-needle aspiration dilemma? Cancer Cytopathol 2013;121:403.
  52. Rossi ED, Larocca LM, Fadda G: The first-line alternative methods to gene expression classifier. Cancer Cytopathol 2013;121:116-119.
  53. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE: Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 2013;98:E1852-E1860.
  54. Costa JL, Sousa S, Justino A, Kay T, Fernandes S, Cirnes L, Schmitt F, Machado JC: Nonoptical massive parallel DNA sequencing of BRCA1 and BRCA2 genes in a diagnostic setting. Hum Mutat 2013;34:629-635.
    External Resources
  55. Costa JL, Gerhard R, Rossi ED, Cirnes L, Justino A, Machado JC, Schmitt FC, et al: Massive parallel sequencing to assess the mutational landscape of fine-needle aspirate samples: a pilot study (abstract 471). 102nd Annu Meet US Can Acad Pathol, Baltimore, 2013.

Article / Publication Details

First-Page Preview
Abstract of Review

Received: April 08, 2014
Accepted: May 06, 2014
Published online: July 16, 2014
Issue release date: November – December

Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 0

ISSN: 0001-5547 (Print)
eISSN: 1938-2650 (Online)

For additional information: https://www.karger.com/ACY


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP